NewAmsterdam Pharma Enters Material Definitive Agreement
Ticker: NAMSW · Form: 8-K · Filed: Dec 13, 2024 · CIK: 1936258
Sentiment: neutral
Topics: material-definitive-agreement, corporate-actions
Related Tickers: NAPX
TL;DR
NAPX signed a big deal, filing shows details.
AI Summary
On December 11, 2024, NewAmsterdam Pharma Company N.V. entered into a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company was formerly known as NewAmsterdam Pharma Co B.V. before a name change on July 1, 2022.
Why It Matters
This filing indicates a significant new contract or partnership for NewAmsterdam Pharma, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks and opportunities, the specifics of which are not fully detailed in this initial 8-K filing.
Key Players & Entities
- NewAmsterdam Pharma Company N.V. (company) — Registrant
- NewAmsterdam Pharma Co B.V. (company) — Former company name
- December 11, 2024 (date) — Date of earliest event reported
- July 1, 2022 (date) — Date of name change
FAQ
What is the nature of the material definitive agreement entered into by NewAmsterdam Pharma?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on December 11, 2024.
When was NewAmsterdam Pharma Company N.V. formerly known as NewAmsterdam Pharma Co B.V.?
The company was formerly known as NewAmsterdam Pharma Co B.V. prior to a name change on July 1, 2022.
What items are included in this 8-K filing?
This 8-K filing includes information on the entry into a material definitive agreement, Regulation FD disclosures, and financial statements and exhibits.
What is the principal executive office address for NewAmsterdam Pharma Company N.V.?
The principal executive office address is Gooimeer 2-35, Naarden, The Netherlands, 1411 DC.
What is the SEC file number for NewAmsterdam Pharma Company N.V.?
The SEC file number for NewAmsterdam Pharma Company N.V. is 001-41562.
Filing Stats: 2,188 words · 9 min read · ~7 pages · Grade level 12.6 · Accepted 2024-12-13 08:28:34
Key Financial Figures
- $24.50 — Shares"), at a public offering price of $24.50 per share and, in lieu of Ordinary Shar
- $24.4999 — arrants") at a public offering price of $24.4999 per Pre-Funded Warrant, which represent
- $0.0001 — price for the Ordinary Shares less the $0.0001 per share exercise price for each such
- $452.6 million — hares, are expected to be approximately $452.6 million after deducting underwriting discounts
Filing Documents
- d916004d8k.htm (8-K) — 44KB
- d916004dex11.htm (EX-1.1) — 287KB
- d916004dex41.htm (EX-4.1) — 66KB
- d916004dex51.htm (EX-5.1) — 56KB
- d916004dex52.htm (EX-5.2) — 11KB
- d916004dex991.htm (EX-99.1) — 13KB
- d916004dex992.htm (EX-99.2) — 13KB
- g916004g1212142443839.jpg (GRAPHIC) — 1KB
- g916004g1212142444142.jpg (GRAPHIC) — 4KB
- g916004g1212142444443.jpg (GRAPHIC) — 6KB
- g916004g1212143659488.jpg (GRAPHIC) — 2KB
- 0001193125-24-277937.txt ( ) — 794KB
- nams-20241211.xsd (EX-101.SCH) — 3KB
- nams-20241211_def.xml (EX-101.DEF) — 14KB
- nams-20241211_lab.xml (EX-101.LAB) — 23KB
- nams-20241211_pre.xml (EX-101.PRE) — 15KB
- d916004d8k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 1.1 Underwriting Agreement, dated as of December 11, 2024, by and among NewAmsterdam Pharma Company N.V., Jefferies LLC, Goldman Sachs & Co. LLC, Leerink Partners LLC, TD Securities (USA) LLC, Guggenheim Securities, LLC and William Blair & Company, L.L.C., as representatives of the several underwriters listed on Schedule A thereto 4.1 Form of Pre-Funded Warrant 5.1 Opinion of NautaDutilh N.V. 5.2 Opinion of Covington & Burling LLP 23.1 Consent of NautaDutilh N.V. (included in Exhibit 5.1) 23.2 Consent of Covington & Burling LLP (included in Exhibit 5.2) 99.1 NewAmsterdam Pharma Company N.V. Press Release, dated December 10, 2024 99.2 NewAmsterdam Pharma Company N.V. Press Release, dated December 11, 2024 104 Cover Page Interactive Data File (embedded with Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NewAmsterdam Pharma Company N.V. Date: December 13, 2024 By: /s/ Michael Davidson Name: Michael Davidson Title: Chief Executive Officer